{
  "state": "district-of-columbia",
  "path": "title-48/chapter-8",
  "sections": [
    {
      "id": "section-48-801.01",
      "number": "48-801.01",
      "heading": "List of most commonly used prescription drugs.",
      "text": "Thirty days prior to each issue date, the Department of Human Services shall furnish to the Office of Consumer Protection a list of the 100 most commonly used prescription drugs.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title I, § 101, 23 DCR 2460; Apr. 7, 1977, D.C. Law 1-114, § 3(a), 23 DCR 8743",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-801.01.html"
    },
    {
      "id": "section-48-801.02",
      "number": "48-801.02",
      "heading": "Posters to be furnished pharmacies; contents.",
      "text": "Ten days prior to each issue date, the Office of Consumer Protection shall furnish to each pharmacy in the District a poster suitable for display of a type style and size so as to be easily readable at a reasonable distance, which:\n\n(1) Lists the 100 most commonly used prescription drugs in 2 commonly prescribed quantities, with space for the current selling price of each quantity;\n\n(2) Lists professional and convenience services, with space for each pharmacy to indicate:\n\n(A) Whether it offers each service; and\n\n(B) The additional charge, if any, for that service;\n\n(3) Contains a heading stating “OUR CURRENT PRESCRIPTION PRICES” and containing spaces for the insertion of the name and address of each pharmacy;\n\n(4) Indicates in simple language that:\n\n(A) The price of a prescription drug is often different at different pharmacies, and that the consumer may want to make a comparison on the cost of a prescription;\n\n(B) The pharmacy may be able to substitute a less expensive drug which is therapeutically equivalent to the one prescribed by the consumer’s doctor, unless the consumer does not approve; and\n\n(C) The consumer has the right to know the exact price of a prescription before it is filled; and\n\n(5) Provides space for each pharmacy to indicate the eligibility and terms of any discount it offers on legend drugs.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title I, § 102, 23 DCR 2460; Apr. 7, 1977, D.C. Law 1-114, § 3(c), 23 DCR 8743",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-801.02.html"
    },
    {
      "id": "section-48-801.03",
      "number": "48-801.03",
      "heading": "Completion and display of posters.",
      "text": "On and after each issue date, each pharmacy shall legibly post on the poster its current selling prices for the 100 most commonly used prescription drugs, the professional and convenience services it offers and the additional charges therefor, and the eligibility and terms of any discount it offers on prescription drugs. The completed poster shall be displayed prominently in the immediate vicinity of the prescription drug service area in such a manner as to be easily visible to consumers without having to obtain permission or assistance of an employee of the pharmacy.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title I, § 103, 23 DCR 2460; Apr. 7, 1977, D.C. Law 1-114, § 3(a), (b), 23 DCR 8743",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-801.03.html"
    },
    {
      "id": "section-48-801.04",
      "number": "48-801.04",
      "heading": "Quotation of prices, services and charges.",
      "text": "The current selling price of all prescription drugs (including those not required to be posted) dispensed by each pharmacy, and the pharmacy’s discounts and professional and convenience services and charges therefor, shall be available and be quoted, correctly and free of charge, by the pharmacy upon request identifying the name, strength, and quantity prescribed by a physician, whether the request is made in person, in writing or by telephone.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title I, § 104, 23 DCR 2460; Apr. 7, 1977, D.C. Law 1-114, § 3(b), (d), 23 DCR 8743",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-801.04.html"
    },
    {
      "id": "section-48-801.05",
      "number": "48-801.05",
      "heading": "Services and drugs to be furnished at prices posted; exception.",
      "text": "No pharmacy may fail to provide to any consumer the discounts and services stated on the poster, under the eligibility, price, and other terms there stated. Every sale of one of the 100 most commonly used prescription drugs, in a quantity and strength which requires the price of the drug to be posted, shall be at the posted price, unless a decrease in price is authorized by subchapter III of this chapter.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title I, § 105, 23 DCR 2460; Apr. 7, 1977, D.C. Law 1-114, § 3(a), 23 DCR 8743",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-801.05.html"
    },
    {
      "id": "section-48-801.06",
      "number": "48-801.06",
      "heading": "Consumer information to reflect actual charges.",
      "text": "A pharmacy may charge any current selling price, discount, service availability or service charge, at any time; provided, that the poster and sources of consumer information are adjusted accordingly.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title I, § 106, 23 DCR 2460",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-801.06.html"
    },
    {
      "id": "section-48-802.01",
      "number": "48-802.01",
      "heading": "Interference with disclosure of price information prohibited.",
      "text": "No person may directly or indirectly prohibit, hinder or restrict or attempt to prohibit or restrict the disclosure by any pharmacy, government agency, or other person, of accurate price information regarding prescription drugs, including such disclosure made by means of advertisements in print or broadcast media, or by other means.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title II, § 201, 23 DCR 2460",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-802.01.html"
    },
    {
      "id": "section-48-803.01",
      "number": "48-803.01",
      "heading": "Generically equivalent drug formulary; therapeutic interchange list.",
      "text": "(a) The formulary of generically equivalent drug products for the District of Columbia shall be the chemical and generic drugs contained in the Food and Drug Administration publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” including all updates issued by the Food and Drug Administration (“Orange Book”).\n\n(b) The Boards of Pharmacy and Medicine may jointly establish a therapeutic interchange list.\n\n(c) If a therapeutic interchange list is established pursuant to subsection (b) of this section:\n\n(1) The Boards of Pharmacy and Medicine shall:\n\n(A) Revise or supplement the therapeutic interchange list as necessary;\n\n(B) Establish procedures to allow a prescriber to consent to the substitution of therapeutically equivalent drug products without prior approval based on the therapeutic interchange list; provided, that a prescriber be allowed to limit authorization to specific conditions or patients and that no prescriber be required for any reason to consent to participation in the therapeutic interchange list; and\n\n(C) Establish and maintain a database, searchable in real time, of those prescribers who have consented to use of the therapeutic interchange list, including any restrictions based on specific conditions or patients; and\n\n(2) The Department of Health shall distribute the therapeutic interchange list to all pharmacies licensed in the District and shall publish it regularly in the District of Columbia Register.\n\n(d) The Board of Pharmacy and the Board of Medicine shall maintain a link on their websites to the current list of biological products determined by the FDA to be interchangeable with a specific biological product.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title III, § 301, 23 DCR 2460; Apr. 7, 1977, D.C. Law 1-114, § 4(a), 23 DCR 8743; Mar. 11, 2010, D.C. Law 18-118, § 2(a), 57 DCR 901",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-803.01.html"
    },
    {
      "id": "section-48-803.02",
      "number": "48-803.02",
      "heading": "Dispensing of generically equivalent drug product or interchangeable biological product.",
      "text": "(1) When a pharmacist receives a prescription for a brand name drug, the pharmacist may dispense a generically equivalent drug product or interchangeable biological product that is listed in the Orange Book; provided, that the pharmacist shall dispense a generically equivalent drug product or interchangeable biological product if requested by the purchaser, except as provided in § 48-803.03.\n\n(2) If a generic substitution is made pursuant to this subsection, the pharmacist shall dispense the generically equivalent drug product or interchangeable biological product in stock having the lowest cost to the person purchasing the drug product.\n\n(b) When a pharmacist receives a prescription for a drug by generic name or interchangeable biological product, the pharmacist shall dispense the listed product in stock that has the lowest cost to the person purchasing the drug product.\n\n(c) Repealed.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title III, § 302, 23 DCR 2460; Apr. 7, 1977, D.C. Law 1-114, § 4(a), 23 DCR 8743; Mar. 11, 2010, D.C. Law 18-118, § 2(b), 57 DCR 901",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-803.02.html"
    },
    {
      "id": "section-48-803.03",
      "number": "48-803.03",
      "heading": "Dispensing of substitute drug products — conditions.",
      "text": "A pharmacist shall not dispense a:\n\n(1) Substitute drug product if the person purchasing the drug product or the patient for whom it is intended indicates a preference for the drug product actually prescribed;\n\n(2) Generically equivalent drug product or interchangeable biological product pursuant to § 48-803.02 if:\n\n(A) The prescriber writes on a prescription order, signed by the prescriber, in the prescriber’s own handwriting “dispense as written” or “D.A.W.” or a similar notation; provided, that checking or initialing a box preprinted or stamped on a prescription form shall not constitute an acceptable notation; or\n\n(B) The prescriber, by telephone, expressly indicates that the prescription is to be dispensed as communicated and this indication is noted in the pharmacist’s own handwriting in the manner provided in subparagraph (A) of this paragraph;\n\n(A) Therapeutically equivalent drug product unless:\n\n(I) The pharmacist or pharmacist’s agent obtains prior approval from the prescriber or the prescriber’s agent before the therapeutically equivalent drug product can be dispensed; or\n\n(II) The therapeutically equivalent drug product is included on the therapeutic interchange list and the endorsing prescriber has given consent to the Boards of Pharmacy and Medicine to permit therapeutic interchange without prior approval;\n\n(ii) The person purchasing the drug product provides consent to the therapeutic interchange;\n\n(iii) The therapeutically equivalent drug product does not have a higher cost to the purchaser than the originally prescribed drug product; provided, that the pharmacist may dispense a more expensive therapeutically equivalent drug product if consent is provided by the purchaser; and\n\n(iv) The dispensing pharmacist, or pharmacist’s agent, has notified the prescriber or prescriber’s agent of the specific drug and dose dispensed.\n\n(B) A pharmacist shall not dispense a therapeutically equivalent drug product for a prescription refill of an antipsychotic, antidepressant, chemotherapy, antiretroviral, or immunosuppressive drug but shall dispense the drug as prescribed.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title III, § 303, 23 DCR 2460; Apr. 7, 1977, D.C. Law 1-114, § 4(a), 23 DCR 8743; Mar. 11, 2010, D.C. Law 18-118, § 2(c), 57 DCR 901",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-803.03.html"
    },
    {
      "id": "section-48-803.03a",
      "number": "48-803.03a",
      "heading": "Dispensing of substitute drug products by pharmacists — notification of substitution.",
      "text": "(a) An individual shall be notified of a drug substitution, including an interchangeable biological product, and provided the right to refuse the substitution prior to purchase of the substitute drug product.\n\n(1) The Department of Health shall create and distribute to all pharmacies signs that state in block letters not less than one inch in height: “This pharmacy may substitute a less expensive drug product that is equivalent to the one prescribed by your health care practitioner unless you request otherwise.\n\n(2) Each pharmacy shall display the sign in a prominent place that has a clear and unobstructed public view at or near the place where prescriptions are dispensed.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title III, § 301; as added Mar. 11, 2010, D.C. Law 18-118, § 2(d), 57 DCR 901",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-803.03a.html"
    },
    {
      "id": "section-48-803.04",
      "number": "48-803.04",
      "heading": "Dispensation of equivalent products by pharmacists — Recording and labeling required.",
      "text": "When a drug is substituted under this subchapter, including the substitution of an interchangeable biological product, the pharmacist shall record on the prescription form the drug substituted by name and manufacturer, and retain the form for inspection by District officials. The pharmacist shall also label the prescription container with the name of the drug substituted, unless the prescribing physician writes “do not label,” or words of similar import, on the prescription, or, in communicating the prescription by telephone, orders that the container not be so labelled.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title III, § 304, 23 DCR 2460; Mar. 11, 2010, D.C. Law 18-118, § 2(e), 57 DCR 901",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-803.04.html"
    },
    {
      "id": "section-48-803.05",
      "number": "48-803.05",
      "heading": "Dispensation of equivalent products by pharmacists — Consideration as practice of medicine or evidence of negligence; failure of physician to specify specific brand.",
      "text": "(a) The substitution of drugs by a licensed pharmacist under this subchapter, including the substitution of an interchangeable biological product shall not constitute the practice of medicine. Nothing in this subchapter shall be construed as authorizing a pharmacist to prescribe any drug or medication.\n\n(b) Substitution of drugs made in accordance with § 48-803.02 shall not constitute evidence of negligence or improper pharmacy practice if the substitution was made within reasonable and prudent pharmacy practice or if the prescribed and substituted drugs were generically equivalent drugs products or an interchangeable biological product as determined under this chapter.\n\n(c) Failure of a licensed physician to specify that a specific brand is necessary for the particular patient shall not constitute evidence of negligence unless the physician had reasonable cause to believe that the health of the patient required the use of that brand and no other.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title III, § 305, 23 DCR 2460; Apr. 7, 1977, D.C. Law 1-114, § 4(b), 23 DCR 8743; Mar. 11, 2010, D.C. Law 18-118, § 2(f), 57 DCR 901",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-803.05.html"
    },
    {
      "id": "section-48-803.06",
      "number": "48-803.06",
      "heading": "Pharmacist notification to prescriber of substitution of interchangeable biological product.",
      "text": "(a) Within 5 business days after dispensing a biological product to a patient, the dispensing pharmacist or the pharmacist's designee shall communicate to the prescriber the specific biological product dispensed, including the name and manufacturer of the biological product; except, that this communication shall not be required if the FDA has not approved an interchangeable biological product for the biological product prescribed to the patient or a refill prescription is not changed from the biological product dispensed on the most recent filling of the prescription.\n\n(1) Except as provided under subsection (c) of this section, the communication required under subsection (a) of this section shall be provided by making an entry that is electronically accessible to the health care provider through:\n\n(A) An interoperable electronic medical records system;\n\n(B) An electronic prescribing technology; or\n\n(C) A pharmacy benefits management system.\n\n(2) Making an entry through a mechanism listed in paragraph (1) of this subsection shall be presumed to provide the communication to the prescriber required under subsection (a) of this section.\n\n(c) If the mechanisms listed in subsection (b)(1) of this section are unavailable, the communication required under subsection (a) of this section may be provided by facsimile, telephone, electronic transmission, or other means.\n\n(d) The requirements under subsections (a) through (c) of this section shall not apply to dispensing pharmacists or their designees at a health maintenance organization that operates as a group model for services furnished through internal pharmacy operations for members and patients of the health maintenance organization.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title III, § 306",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-803.06.html"
    },
    {
      "id": "section-48-804.01",
      "number": "48-804.01",
      "heading": "Violations of posting provisions.",
      "text": "(a) Any pharmacy which sells a legend drug in violation of § 48-801.03, § 48-801.04, or § 48-801.05 is liable to the buyer, or the provider or insurer of the buyer, for the full amount charged for the drug.\n\n(b) Civil fines, penalties, and fees may be imposed as alternative sanctions for any infraction of the provisions of this subchapter, or any rules or regulations issued under the authority of this subchapter, pursuant to Chapter 18 of Title 2. Adjudication of any infraction of this subchapter shall be pursuant to Chapter 18 of Title 2.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title IV, § 401, 23 DCR 2460; Mar. 8, 1991, D.C. Law 8-237, § 20, 38 DCR 314",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-804.01.html"
    },
    {
      "id": "section-48-804.02",
      "number": "48-804.02",
      "heading": "Restraints of trade.",
      "text": "Any person who, by any means, interferes with, prevents, discourages, or attempts to interfere with, prevent, or discourage: (1) any disclosure of, or attempt to disclose, or action necessary to disclose, substantially accurate prices, discounts, services, or other information concerning any prescription drug, whether or not such disclosure is authorized or directed in this chapter, or is through any media or other form of communication, or is made or to be made by any publisher, broadcaster, pharmacy, pharmacist, advertiser, drug manufacturer, wholesaler, or chain, government agency, or any other person; or (2) any retail drug price-setting, substitution, or marketing policy or action required, encouraged or permitted by, or consistent with this chapter; has committed a restraint of trade, and has caused a tortious injury in the District of Columbia as described in § 13-423(a)(3) and (4), and shall be liable for treble civil damages to each and every person (including a pharmacy or pharmacist), health insurer, and government agency the object of or injured by such interference, prevention, discouragement, or attempt to interfere, prevent, or discourage. Any action which jeopardizes in any way, or raises the net price of, the supply from manufacturers or wholesalers of drugs to any pharmacy, government agency, health insurer, or person providing or paying for a drug in the District may comprise such an interference, prevention, discouragement, or attempt.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title IV, § 402, 23 DCR 2460",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-804.02.html"
    },
    {
      "id": "section-48-804.03",
      "number": "48-804.03",
      "heading": "Inspection of pricing records and practices; cease and desist orders.",
      "text": "After reasonable notice, the Office of Consumer Protection may inspect the pricing records and practices of any pharmacy or other person, to assure compliance with this chapter. After appropriate notice and hearing, the Office may, if it finds that any person has violated this chapter, issue a cease and desist order against continued or future violation, and such other orders as may otherwise be within powers of that Office.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, title IV, § 403, 23 DCR 2460",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-804.03.html"
    },
    {
      "id": "section-48-804.51",
      "number": "48-804.51",
      "heading": "Definitions.",
      "text": "For the purposes of this chapter, the term:\n\n(1) “Agent” means an individual who:\n\n(A) Is under the immediate and personal supervision of a prescriber or pharmacist and has written authorization, which shall be available for review upon request, to act on behalf of or at the direction of the prescriber or pharmacist when seeking or obtaining approval of a therapeutic interchange; or\n\n(B) If not under the immediate and personal supervision of a prescriber or pharmacist, holds a license to administer drugs, such as a nurse, physician’s assistant, or other pharmacist.\n\n(1A) \"Biological product\" shall have the same meaning as provided in 42 U.S.C. § 262.\n\n(2) “Endorsing prescriber” means a prescriber who has reviewed the therapeutic interchange list and has notified the Boards of Pharmacy and Medicine in writing that he or she has agreed to allow the therapeutic interchange.\n\n(2A) \"Interchangeable biological product\" means a biological product that is:\n\n(A) Licensed and determined by the United States Food and Drug Administration to meet the standards for interchangeability under 42 U.S.C. § 262(k)(4); or\n\n(B) Determined to be biosimilar to and interchangeable with a reference biological product as stated in the latest edition of, or supplement to, the United States and Food and Drug administration's (\"FDA\") publication, \"Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations\" (known as the Purple Book).\n\n(3) “Issue date” means the 1st day of the 4th full calendar month after April 7, 1977, and the day following the end of each year after the 1st such issue date.\n\n(4) “Most commonly used prescription drugs” means the prescription drug products that were most frequently paid for by the Medicaid program operated by the District of Columbia government under a state plan filed in accordance with section 1902 of the Social Security Act (§ 1396a of Title 42, United States Code), in the 3 consecutive months ending 60 days before an issue date.\n\n(5) “Person” means any individual, partnership, corporation, organization, or association.\n\n(6) “Pharmacy” means a pharmacy that provides services to the public on an outpatient basis.\n\n(7) “Prescriber” means a person who is licensed, registered, or otherwise authorized by the District to prescribe and administer prescription drugs for human use in the course of a professional practice.\n\n(8) “Substitute drug product” means a drug product different than the one originally prescribed by a prescriber.\n\n(9) “Therapeutic interchange” means the dispensing of chemically dissimilar but therapeutically equivalent drug products.\n\n(10) “Therapeutic interchange list” means a list of therapeutically equivalent drug products.\n\n(11) “Therapeutically equivalent drug product” means a drug product that is chemically dissimilar but produces essentially the same therapeutic outcome.",
      "history": "Sept. 10, 1976, D.C. Law 1-81, § 2, 23 DCR 2460; Apr. 7, 1977, D.C. Law 1-114, § 2, 23 DCR 8743; Mar. 11, 2010, D.C. Law 18-118, § 2(g), 57 DCR 901",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-804.51.html"
    },
    {
      "id": "section-48-831.01",
      "number": "48-831.01",
      "heading": "Findings and declaration of intent.",
      "text": "The Council finds that:\n\n(1) Affordability is critical in providing access to prescription drugs for District of Columbia residents.\n\n(2) AccessRx enables the District to take steps to make prescription drugs more affordable for qualified District residents, thereby increasing the overall health of District residents, promoting healthy communities, and protecting the public health and welfare.\n\n(3) AccessRx can be integrated with any District-wide program for the uninsured.\n\n(4) The intent of AccessRx is not to discourage employers from offering or paying for prescription drug benefits for their employees or to replace employer-sponsored prescription drug benefit plans that provide benefits comparable to those made available to qualified District residents under AccessRx.",
      "history": "May 18, 2004, D.C. Law 15-164, § 101, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.01.html"
    },
    {
      "id": "section-48-831.02",
      "number": "48-831.02",
      "heading": "Definitions.",
      "text": "For the purposes of this chapter, the term:\n\n(1) “AccessRx” means the District of Columbia AccessRx program established by § 48-831.03.\n\n(2) “Average wholesale price” means the wholesale price charged for a specific commodity that is assigned by the drug wholesaler and is listed in a nationally recognized drug pricing registry that is updated daily and charged to the retail pharmacy.\n\n(3) “Basic component of AccessRx” includes the provision of drugs and medications for cardiac conditions and high blood pressure, diabetes, arthritis, anticoagulation, hyperlipidemia, osteoporosis, chronic obstructive pulmonary disease and asthma, incontinence, thyroid diseases, glaucoma, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and other conditions approved by the Department. The term “basic component of AccessRx” shall also include the provision of over-the-counter medications that are prescribed by a health care provider and approved as cost-effective by the Department.\n\n(A) “Covered entity” means:\n\n(i) Any hospital or medical service organization, insurer, health coverage plan, or health maintenance organization licensed in the District that contracts with another entity to provide prescription drug benefits for its customers or clients;\n\n(ii) Any health program administered by the Department or the District in its capacity as provider of health coverage; or\n\n(iii) Any employer, labor union, or other group of persons organized in the District that contracts with another entity to provide prescription drug benefits for its employees or members who are employed or reside in the District of Columbia.\n\n(B) The term “covered entity” does not include a health plan that provides coverage only for accidental injury, specified disease, hospital indemnity, Medicare supplement, disability income, long-term care, or other limited benefit health insurance policies and contracts.\n\n(5) “Covered individual” means a member, participant, enrollee, contract holder, policy holder, or beneficiary of a covered entity who is provided a prescription drug benefit by the covered entity. The term “covered individual” includes a dependent or other person provided a prescription drug benefit through a policy, contract, or plan for a covered individual.\n\n(6) “Department” means the Department of Health.\n\n(7) “Director” means the Director of the Department of Health.\n\n(8) “District” means the District of Columbia.\n\n(9) “Generic drug” means a chemically equivalent copy of a brand-name drug with an expired patent.\n\n(10) “Initial discounted price” for a drug means the price the Department pays D.C. Medicaid participating retail pharmacies for that drug for District of Columbia Medicaid recipients.\n\n(11) “Labeler” means an entity or person that receives prescription drugs from a manufacturer or wholesaler and repackages those drugs for later retail sale and that has a labeler code from the federal Food and Drug Administration under 21 C.F.R. § 207.20.\n\n(12) “Manufacturer” means a manufacturer of prescription drugs and includes a subsidiary or affiliate of a manufacturer.\n\n(13) “Marketing” means advertising and promotional activities, including, but not limited to, the activities described in § 48-833.03.\n\n(14) “National Drug Code registration number” means the number registered for a drug pursuant to the listing system established by the United States Food and Drug Administration under section 510 of the Federal Food, Drug, and Cosmetic Act, approved October 10, 1962 (76 Stat. 794; 21 U.S.C. § 360).\n\n(15) “Participating retail pharmacy” or “retail pharmacy” means a retail pharmacy located in the District, or another business licensed to dispense prescription drugs in the District, that participates in the program.\n\n(16) “Pharmacy benefits management” means a service provided to covered entities to facilitate the provision of prescription drug benefits to covered individuals for dispensation within the District of Columbia, including negotiating pricing and other terms with drug manufacturers and retails pharmacies. “Pharmacy benefits management” may include any or all of the following:\n\n(A) Claims processing, retail network management, and payment of claims to pharmacies for prescription drugs dispensed to covered individuals for dispensation within the District of Columbia;\n\n(B) Clinical formulary development and management services;\n\n(C) Rebate contracting and administration;\n\n(D) Certain patient compliance, therapeutic intervention, and generic substitution programs; and\n\n(E) Disease management programs.\n\n(17) “Pharmacy benefits manager” means an entity that performs pharmacy benefits management. The term “pharmacy benefits manager” includes a person or entity acting for a pharmacy benefits manager in a contractual or employment relationship in the performance of pharmacy benefits management for a covered entity.\n\n(18) “Qualified resident” means a resident of the District who is eligible for the AccessRx program pursuant to this subchapter.\n\n(19) “Secondary discounted price” means the initial discounted price minus any further discounts paid for out of the AccessRx Fund.\n\n(20) “Supplemental component of AccessRx” includes all prescription drugs and medications provided under the D.C. Medicaid program excluding those provided pursuant to the basic component of AccessRx.",
      "history": "May 18, 2004, D.C. Law 15-164, § 102, 51 DCR 3688; Mar. 2, 2007, D.C. Law 16-192, § 5062(a), 53 DCR 6899",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.02.html"
    },
    {
      "id": "section-48-831.03",
      "number": "48-831.03",
      "heading": "Establishment of AccessRx.",
      "text": "(a) AccessRx is hereby established. AccessRx shall be administered by the Department, which shall utilize, among other things, manufacturer rebates, pharmacy discounts, and aggregate purchasing to reduce prescription drug prices. In addition, the Department shall investigate the purchase of prescription drugs from outside of the United States.\n\n(b) The Department shall administer AccessRx and other medical and pharmaceutical assistance programs in a manner that is advantageous to the programs and to the enrollees in those programs. In implementing this subchapter, the Department may coordinate the other programs and AccessRx and may take actions to enhance efficiency, reduce the cost of prescription drugs, and maximize the benefits to the programs and enrollees, including providing the benefits of AccessRx to enrollees in other programs.",
      "history": "May 18, 2004, D.C. Law 15-164, § 103, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.03.html"
    },
    {
      "id": "section-48-831.04",
      "number": "48-831.04",
      "heading": "Cost containment and savings with respect to existing publicly funded pharmaceutical programs.",
      "text": "The Department shall make every effort to reduce and contain the cost of prescription drugs purchased for publicly funded pharmaceutical assistance programs, including D.C. Medicaid, the D.C. Health Care Alliance, and the Department of Mental Health. These efforts shall include manufacturer rebates, pharmacy discounts, and reductions through aggregate purchases, and may include importation of pharmaceuticals from outside of the United States. These savings shall be deposited in the AccessRx Fund established in § 48-831.10",
      "history": "May 18, 2004, D.C. Law 15-164, § 104, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.04.html"
    },
    {
      "id": "section-48-831.05",
      "number": "48-831.05",
      "heading": "Rebate agreement.",
      "text": "A drug manufacturer or labeler that sells prescription drugs in the District through any publicly funded pharmaceutical assistance program shall enter into a rebate agreement with the Department under AccessRx. The rebate agreement shall require the manufacturer or labeler to make rebate payments to the District for deposit in the AccessRx Fund each calendar quarter or according to a schedule established by the Department.",
      "history": "May 18, 2004, D.C. Law 15-164, § 105, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.05.html"
    },
    {
      "id": "section-48-831.06",
      "number": "48-831.06",
      "heading": "Rebate amount.",
      "text": "(a) The Director of the Department shall negotiate the amount of the rebate required from a manufacturer or labeler in accordance with this subchapter.\n\n(b) The Director shall take into consideration the rebate calculated under the Medicaid Rebate Program pursuant to section 1927 of the Social Security Act, approved November 5, 1990 (104 Stat. 1388-143; 42 U.S.C. § 1396r-8), the average wholesale price of prescription drugs, and any other information on prescription drug prices and price discounts.\n\n(c) The Director shall use the Director’s best efforts to obtain an initial rebate amount equal to or greater than the rebate calculated under the Medicaid program pursuant to 42 U.S.C. § 1396r-8.\n\n(d) With respect to the rebate that takes effect on October 1, 2005 pursuant to § 48-831.33(d), the Director shall use the Director’s best efforts to obtain an amount equal to or greater than the amount of any discount, rebate, or price reduction for prescription drugs provided to the federal government. If the Department is not able to achieve the rebate amount described by this subsection, the Department shall report that fact to the standing committee of the Council having jurisdiction over the Department.",
      "history": "May 18, 2004, D.C. Law 15-164, § 106, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.06.html"
    },
    {
      "id": "section-48-831.07",
      "number": "48-831.07",
      "heading": "Operation of program.",
      "text": "(a) Participating retail pharmacies shall submit claims to the Department to verify the amount charged to qualified residents and to receive reimbursement.\n\n(b) The Department shall not impose transaction charges on participating retail pharmacies that submit claims or receive payments under AccessRx.\n\n(c) On a periodic basis, to be established by the Department, the Department shall reimburse a participating retail pharmacy for:\n\n(1) The discounted price provided to uninsured qualified residents pursuant to § 48-831.33; and\n\n(2) Prescription drugs dispensed to low-income elderly pursuant to § 48-831.23.\n\n(d) The Department shall conduct ongoing quality assurance activities similar to those used in the D.C. Medicaid program.\n\n(e) The Department shall collect utilization data from participating retail pharmacies submitting claims necessary to calculate the amount of the rebate from the manufacturer or labeler. The Department shall protect the confidentiality of all information subject to confidentiality protection under District or federal law, rule or regulation.",
      "history": "May 18, 2004, D.C. Law 15-164, § 107, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.07.html"
    },
    {
      "id": "section-48-831.08",
      "number": "48-831.08",
      "heading": "Discrepancies in rebate amounts.",
      "text": "(1) Upon receipt of the data from the Department, the manufacturer or labeler shall calculate the quarterly payment. If a discrepancy is discovered, the Department may, at its expense, hire a mutually agreed-upon independent auditor to verify the manufacturer’s calculation. If a discrepancy is still found, the manufacturer or labeler shall justify its calculation or make payments to the Department for any additional amount due. The manufacturer or labeler may, at its expense, hire a mutually agreed-upon independent auditor to verify the accuracy of the utilization data provided by the Department. If a discrepancy is discovered, the Department shall justify its data or refund any excess payment to the manufacturer or labeler.\n\n(2) If the dispute over the rebate amount is not resolved, a request for a hearing with supporting documentation shall be submitted to the Office of Administrative Hearings. Failure to resolve the dispute may be cause for terminating the drug rebate agreement and denying payment to the manufacturer or labeler for any drugs.\n\n(b) All prescription drugs of a manufacturer or labeler that enters into a rebate agreement that appear on the list of approved drugs shall be immediately available and the cost of the drugs shall be reimbursed, except as provided in this section.",
      "history": "May 18, 2004, D.C. Law 15-164, § 108, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.08.html"
    },
    {
      "id": "section-48-831.09",
      "number": "48-831.09",
      "heading": "Action with regard to nonparticipating manufacturers and labelers.",
      "text": "(a) The names of manufacturers and labelers who do and do not enter into rebate agreements pursuant to this subchapter are public information. The Department shall release this information to health care providers and the public on a regular basis. The Department also shall publicize participation by manufacturers and labelers that is of particular benefit to the public.\n\n(b) The Department shall impose prior authorization requirements, as permitted by law, in all publicly funded pharmaceutical assistance programs to the extent the Department determines it is appropriate to do so in order to encourage manufacturer and labeler participation in AccessRx, as long as the additional prior authorization requirements remain consistent with the goals of the D.C. Medicaid program and Title 19 of the Social Security Act, approved July 30, 1965 (79 Stat. 343; 42 U.S.C. § 1396 et seq.).",
      "history": "May 18, 2004, D.C. Law 15-164, § 109, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.09.html"
    },
    {
      "id": "section-48-831.10",
      "number": "48-831.10",
      "heading": "AccessRx Fund.",
      "text": "(a) The AccessRx Fund is established as a nonlapsing, dedicated fund, into which shall be deposited revenue from manufacturers and labelers that pay rebates pursuant to this subchapter and any appropriations or allocations designated for the AccessRx Fund, along with accruing interest, to be used for the purposes specified in subsection (b) of this section.\n\n(b) All funds in the AccessRx Fund, including any surplus or interest, shall be used to:\n\n(1) Reimburse retail pharmacies for discounted prices provided to uninsured qualified residents pursuant to § 48-831.33;\n\n(2) Pay benefits described in § 48-831.23; and\n\n(3) Reimburse the Department for contracted services, including pharmacy claims processing fees, administrative and associated computer costs, and other reasonable program costs.\n\n(c) The funds deposited in the AccessRx Fund shall not revert to the General Fund but shall continually be available for the uses designated in subsection (b) of this section, subject to authorization by Congress in an appropriations act.",
      "history": "May 18, 2004, D.C. Law 15-164, § 110, 51 DCR 3688; Mar. 2, 2007, D.C. Law 16-191, § 88(a), 53 DCR 6794",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.10.html"
    },
    {
      "id": "section-48-831.11",
      "number": "48-831.11",
      "heading": "Eligibility procedures.",
      "text": "The Department shall:\n\n(1) Establish simplified procedures for determining eligibility and issuing AccessRx enrollment cards to qualified residents;\n\n(2) Undertake outreach efforts to build public awareness of AccessRx and maximize enrollment of qualified residents; and\n\n(3) Adjust the requirements and terms of AccessRx to accommodate any new federally funded prescription drug program.",
      "history": "May 18, 2004, D.C. Law 15-164, § 111, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.11.html"
    },
    {
      "id": "section-48-831.12",
      "number": "48-831.12",
      "heading": "Method of prescribing or ordering drugs.",
      "text": "The method of prescribing or ordering drugs may include, but is not limited to, the use of standard or larger prescription refill sizes in order to minimize operational costs and maximize economy. Unless the prescribing physician indicates otherwise, the use of the lowest cost generic or chemically equivalent drugs is required; provided, that these drugs are of the same quality and have the same mode of delivery as is provided to the general public, consistent with good pharmaceutical practice.",
      "history": "May 18, 2004, D.C. Law 15-164, § 112, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.12.html"
    },
    {
      "id": "section-48-831.13",
      "number": "48-831.13",
      "heading": "Third-party administration.",
      "text": "The Department may contract with one or more third parties to administer any or all components of AccessRx, including outreach, eligibility, claims, administration, and rebate recovery and redistribution.",
      "history": "May 18, 2004, D.C. Law 15-164, § 113, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.13.html"
    },
    {
      "id": "section-48-831.14",
      "number": "48-831.14",
      "heading": "Waivers.",
      "text": "The Department may seek any waivers of federal law, rule or regulation necessary to implement the provisions of this chapter.",
      "history": "May 18, 2004, D.C. Law 15-164, § 114, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.14.html"
    },
    {
      "id": "section-48-831.15",
      "number": "48-831.15",
      "heading": "Annual summary report.",
      "text": "The Department shall submit a written report on the enrollment and financial status of AccessRx to the Council by the 2nd week of January each year.",
      "history": "May 18, 2004, D.C. Law 15-164, § 115, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.15.html"
    },
    {
      "id": "section-48-831.16",
      "number": "48-831.16",
      "heading": "Agreements with governments of other jurisdictions and other entities.",
      "text": "The District may negotiate and enter into purchasing alliances and regional strategies with the governments of other jurisdictions, and with other public and private entities, for the purpose of reducing prescription drug prices for residents of the District.",
      "history": "May 18, 2004, D.C. Law 15-164, § 116, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.16.html"
    },
    {
      "id": "section-48-831.17",
      "number": "48-831.17",
      "heading": "Rulemaking.",
      "text": "The Mayor is authorized to issue any rules necessary to implement the provisions of this subchapter.",
      "history": "May 18, 2004, D.C. Law 15-164, § 117, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.17.html"
    },
    {
      "id": "section-48-831.21",
      "number": "48-831.21",
      "heading": "Establishment of AccessRx for the low-income elderly.",
      "text": "(a) The Department shall conduct a program to provide low-cost prescription and nonprescription drugs, medications, and medical supplies to low-income elderly individuals (“AccessRx for low-income elderly”).\n\n(b) The Director shall provide sufficient personnel to ensure efficient administration of the program. The extent and magnitude of the program shall be determined by the Director on the basis of the calculated need of the recipient population and the available funds.\n\n(c) The Department may not spend more on this program than is available through appropriations from the General Fund, dedicated revenue, federal or other grants, and other established and committed funding sources. The Director may accept, for the purpose of carrying out this program:\n\n(1) Federal funds appropriated under any federal law relating to the furnishing of free or low-cost drugs to elderly individuals, and may take such action as is necessary for the purposes of carrying out that federal law; and\n\n(2) Funds that may be available from any other agency of government, individual, group, or corporation.",
      "history": "May 18, 2004, D.C. Law 15-164, § 121, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.21.html"
    },
    {
      "id": "section-48-831.22",
      "number": "48-831.22",
      "heading": "Eligibility for low-income elderly.",
      "text": "To be eligible, an individual shall:\n\n(1) Be a resident of the District;\n\n(2) Be at least 62 years of age; and\n\n(3) Have a household income that is not more than 200% of the federal poverty level.",
      "history": "May 18, 2004, D.C. Law 15-164, § 122, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.22.html"
    },
    {
      "id": "section-48-831.23",
      "number": "48-831.23",
      "heading": "Payment for drugs by low-income elderly.",
      "text": "(a) The Director shall establish the amount of payment to be made by eligible low-income elderly individuals toward the cost of prescription or nonprescription drugs, medications, and medical supplies furnished under AccessRx for low-income elderly; provided, that:\n\n(1) The total cost paid by the low-income elderly individual for any covered purchase of a prescription or nonprescription drug or medication provided under the basic component of AccessRx does not exceed 20% of the price allowed for that prescription under AccessRx rules, or $2, whichever is greater; and\n\n(2) For the supplemental component of AccessRx, except as otherwise provided in this section, the total cost paid by the low-income elderly individual for any covered purchase of a prescription drug or medication shall not exceed 50% of the price allowed for that prescription under AccessRx.\n\n(b) Prior to January 1, 2006, the Director shall establish annual limits on the costs incurred by eligible household members for prescription or nonprescription drugs or medications covered under AccessRx for low-income elderly. After the annual limits have been established, beginning on January 1, 2007, AccessRx for low-income elderly shall pay 80% of the cost of all prescription or nonprescription drugs or medications covered by the supplemental component of AccessRx. The limits shall be set by the Director by regulation as necessary to operate the program within the AccessRx for low-income elderly budget.",
      "history": "May 18, 2004, D.C. Law 15-164, § 123, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.23.html"
    },
    {
      "id": "section-48-831.31",
      "number": "48-831.31",
      "heading": "Establishment of AccessRx for uninsured District residents.",
      "text": "The Department shall conduct a program to negotiate low-cost prescription and nonprescription drugs, medications, and medical supplies for uninsured District residents (“AccessRx for uninsured”). The Director shall provide sufficient personnel to ensure efficient administration of the program. The extent and magnitude of the program shall be determined by the Director on the basis of the calculated need of the recipient population and available funds.",
      "history": "May 18, 2004, D.C. Law 15-164, § 131, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.31.html"
    },
    {
      "id": "section-48-831.32",
      "number": "48-831.32",
      "heading": "Eligibility of the uninsured.",
      "text": "To be eligible, an individual shall:\n\n(1) Be a resident of the District;\n\n(2) Have a household income that is not more than 350% of the federal poverty level; and\n\n(3) Not be enrolled in any public or private medical insurance program.",
      "history": "May 18, 2004, D.C. Law 15-164, § 132, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.32.html"
    },
    {
      "id": "section-48-831.33",
      "number": "48-831.33",
      "heading": "Discounted prices for uninsured qualified residents.",
      "text": "(a) Any participating retail pharmacy that sells prescription drugs covered by a rebate agreement pursuant to § 48-831.05 shall discount the retail price of those drugs sold to uninsured qualified residents.\n\n(b) The Department shall establish discounted prices for drugs covered by a rebate agreement and shall promote the use of efficacious and reduced-cost drugs, taking into consideration reduced prices for state and federally capped drug programs, differential dispensing fees, administrative overhead, and incentive payments.\n\n(c) Beginning January 1, 2005, a participating retail pharmacy shall offer the initial discounted price.\n\n(d) Beginning no later than October 1, 2005, a participating retail pharmacy shall offer the secondary discounted price, if available.",
      "history": "May 18, 2004, D.C. Law 15-164, § 133, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.33.html"
    },
    {
      "id": "section-48-831.41",
      "number": "48-831.41",
      "heading": "Establishment of AccessRx Pharmaceutical Resource Center.",
      "text": "The Department shall conduct a program to provide life saving prescription and nonprescription medications and medical supplies by enrolling eligible individuals into pharmaceutical assistance programs. Of the funds appropriated for the Department of Health for fiscal year 2006, the Director shall enter into a contract with the Archdiocesan Health Care Network, Catholic Charities in an amount up to $1.956 million to operate and administer the program and provide sufficient personnel to ensure appropriate oversight of the program.",
      "history": "May 18, 2004, D.C. Law 15-164, § 141; as added Oct. 20, 2005, D.C. Law 16-33, § 5072, 52 DCR 7503; Mar. 2, 2007, D.C. Law 16-192, § 5062(b), 53 DCR 6899",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.41.html"
    },
    {
      "id": "section-48-831.42",
      "number": "48-831.42",
      "heading": "Eligibility.",
      "text": "(a) To be eligible, an individual shall:\n\n(1) Be a resident of the District;\n\n(2) Have a household income not exceeding 300% of the federal poverty level; and\n\n(3) Lack prescription coverage.\n\n(b) Eligibility shall be determined by the contract organization administering the program.\n\n(c) Eligibility for District Medicaid, DC Healthcare Alliance, and other public programs shall be screened at the time an individual seeks to enroll in the program, and appropriate referrals shall be made to the Income Maintenance Administration in the Department of Human Services.",
      "history": "May 18, 2004, D.C. Law 15-164, § 142; as added Oct. 20, 2005, D.C. Law 16-33, § 5072, 52 DCR 7503",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-831.42.html"
    },
    {
      "id": "section-48-832.01",
      "number": "48-832.01",
      "heading": "Fiduciary duty.",
      "text": "(a) A pharmacy benefits manager owes a fiduciary duty to a covered entity and shall discharge that duty in accordance with all applicable laws. In performance of that duty, a pharmacy benefits manager shall adhere to the practices set forth in this section.\n\n(1) A pharmacy benefits manager shall:\n\n(A) Perform its duties with care, skill, prudence, and diligence and in accordance with the standards of conduct applicable to a fiduciary in an enterprise of a like character and with like aims; and\n\n(B) Repealed.\n\n(C) Notify the covered entity in writing of any activity, policy or practice of the pharmacy benefits manager that directly or indirectly presents any conflict of interest with the duties imposed by this subchapter; and\n\n(2) A pharmacy benefits manager that receives from any drug manufacturer or labeler any payment or benefit of any kind in connection with the utilization of prescription drugs by covered individuals, including payments or benefits based on volume of sales or market share, shall pass that payment or benefit on in full to the covered entity. This provision does not prohibit the covered entity from agreeing by contract to compensate the pharmacy benefits manager by returning a portion of the benefit or payment to the pharmacy benefits manager.\n\n(1) Upon request by a covered entity, a pharmacy benefits manager retained by that covered entity shall:\n\n(A) Provide information showing the quantity of drugs purchased by the covered entity and the net cost to the covered entity for the drugs. This information shall include all rebates, discounts, and other similar payments. If requested by the covered entity, the pharmacy benefits manager shall provide such quantity and net cost information on a drug-by-drug basis by National Drug Code registration number rather than on an aggregated basis; and\n\n(B) Disclose to the covered entity all financial terms and arrangements for remuneration of any kind that apply between the pharmacy benefits manager and any prescription drug manufacturer or labeler, including, without limitation, formulary management and drug-substitution programs, educational support, claims processing, and data sales fees.\n\n(2) A pharmacy benefits manager providing information to a covered entity under this section may designate that information as confidential. Information designated as confidential may not be disclosed by the covered entity to any other person or entity without the consent of the pharmacy benefits manager, unless ordered by a court of the District for good cause shown.\n\n(d) The following provisions apply to the dispensation of a substitute prescription drug for a prescribed drug to a covered individual:\n\n(1) Repealed.\n\n(2) If the substitute drug costs more than the prescribed drug, the pharmacy benefits manager shall disclose to the covered entity the cost of both drugs and any benefit or payment directly or indirectly accruing to the pharmacy benefits manager as a result of the substitution.\n\n(3) The pharmacy benefits manager shall transfer in full to the covered entity any benefit or payment received in any form by the pharmacy benefits manager as a result of a prescription drug substitution under paragraph (2) of this subsection.",
      "history": "May 18, 2004, D.C. Law 15-164, § 201, 51 DCR 3688; Mar. 2, 2007, D.C. Law 16-192, § 5062(c), 53 DCR 6899; Sept. 26, 2012, D.C. Law 19-171, § 137, 59 DCR 6190",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-832.01.html"
    },
    {
      "id": "section-48-832.02",
      "number": "48-832.02",
      "heading": "Compliance.",
      "text": "Compliance with the requirements of this subchapter is required in all contracts between a pharmacy benefits manager and a covered entity entered into in the District of Columbia or by a covered entity in the District of Columbia executed after May 18, 2004.",
      "history": "May 18, 2004, D.C. Law 15-164, § 202, 51 DCR 3688; Mar. 2, 2007, D.C. Law 16-192, § 5062(d), 53 DCR 6899",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-832.02.html"
    },
    {
      "id": "section-48-832.03",
      "number": "48-832.03",
      "heading": "Enforcement.",
      "text": "A violation of this subchapter is a violation of Chapter 39 of Title 28, for which a fine of not more than $10,000 may be adjudged.",
      "history": "May 18, 2004, D.C. Law 15-164, § 203, 51 DCR 3688; Mar. 2, 2007, D.C. Law 16-191, § 88(b), 53 DCR 6794",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-832.03.html"
    },
    {
      "id": "section-48-833.01",
      "number": "48-833.01",
      "heading": "Requirement to disclose prescription drug marketing costs.",
      "text": "A manufacturer or labeler of prescription drugs dispensed in the District that employs, directs, or utilizes marketing representatives in the District shall report marketing costs for prescription drugs in the District. These marketing costs shall be reported to the Department for the purposes of assisting the District in its role as a purchaser of prescription drugs and as an administrator of prescription drug programs, enabling the District to determine the scope of prescription drug marketing costs and their effect on the cost, utilization, and delivery of health care services, and furthering the role of the District as guardian of the public interest.",
      "history": "May 18, 2004, D.C. Law 15-164, § 301, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-833.01.html"
    },
    {
      "id": "section-48-833.02",
      "number": "48-833.02",
      "heading": "Manner of reporting.",
      "text": "By July 1st of each year, a manufacturer or labeler of prescription drugs that directly or indirectly distributes prescription drugs for dispensation to residents of the District shall file a report with the Department in the form and manner provided by the Department. The report shall be accompanied by payment of a fee, as set by the Department in rule, to support the work of the Department under this subchapter.",
      "history": "May 18, 2004, D.C. Law 15-164, § 302, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-833.02.html"
    },
    {
      "id": "section-48-833.03",
      "number": "48-833.03",
      "heading": "Content of annual report by manufacturer or labeler.",
      "text": "(a) Except as provided in subsection (b) of this section, the annual report filed pursuant to § 48-833.02 shall include the following information as it pertains to marketing activities conducted within the District in a form that provides the value, nature, purpose, and recipient of the expense:\n\n(1) All expenses associated with advertising, marketing, and direct promotion of prescription drugs through radio, television, magazines, newspapers, direct mail, and telephone communications as they pertain to District residents;\n\n(2) With regard to all persons and entities licensed to provide health care in the District, including health care professionals and persons employed by them in the District, carriers licensed under Title 31, health plans and benefits managers, pharmacies, hospitals, nursing facilities, clinics, and other entities licensed to provide health care in the District, the following information:\n\n(A) All expenses associated with educational or informational programs, materials, and seminars, and remuneration for promoting or participating in educational or informational sessions, regardless of whether the manufacturer or labeler provides the educational or informational sessions or materials;\n\n(B) All expenses associated with food, entertainment, gifts valued at more than $25, and anything provided to a health care professional for less than market value;\n\n(C) All expenses associated with trips and travel; and\n\n(D) All expenses associated with product samples, except for samples that will be distributed free of charge to patients; and\n\n(3) The aggregate cost of all employees or contractors of the manufacturer or labeler who directly or indirectly engage in the advertising or promotional activities listed in paragraphs (1) and (2) of this subsection, including all forms of payment to those employees. The cost reported under this paragraph shall reflect only that portion of payment to employees or contractors that pertains to activities within the District or to recipients of the advertising or promotional activities who are residents of or are employed in the District.\n\n(b) The following marketing expenses are not subject to the requirements of this subchapter:\n\n(1) Expenses of $25 or less;\n\n(2) Reasonable compensation and reimbursement for expenses in connection with a bona fide clinical trial of a new vaccine, therapy, or treatment; and\n\n(3) Scholarships and reimbursement of expenses for attending a significant educational, scientific, or policy-making conference or seminar of a national, regional, or specialty medical or other professional association if the recipient of the scholarship is chosen by the association sponsoring the conference or seminar.",
      "history": "May 18, 2004, D.C. Law 15-164, § 303, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-833.03.html"
    },
    {
      "id": "section-48-833.04",
      "number": "48-833.04",
      "heading": "Department reports.",
      "text": "By November 30th of each year, the Department shall provide an annual report, providing information in aggregate form, on prescription drug marketing expenses to the Council and the Corporation Counsel. By January 1, 2005, and every 2 years thereafter, the Department shall provide a report to the Council and the Corporation Counsel, providing information in aggregate form, containing an analysis of the data submitted to the Department, including the scope of prescription drug marketing activities and expenses and their effect on the cost, utilization, and delivery of health care services, and any recommendations with regard to marketing activities of prescription drug manufacturers and labelers.",
      "history": "May 18, 2004, D.C. Law 15-164, § 304, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-833.04.html"
    },
    {
      "id": "section-48-833.05",
      "number": "48-833.05",
      "heading": "Confidentiality; public information.",
      "text": "Notwithstanding any provision of law to the contrary, information submitted to the Department pursuant to this subchapter is confidential and is not a public record. Data compiled in aggregate form by the Department for the purposes of reporting required by this subchapter is a public record as long as it does not reveal trade information that is protected by District, state, or federal law.",
      "history": "May 18, 2004, D.C. Law 15-164, § 305, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-833.05.html"
    },
    {
      "id": "section-48-833.06",
      "number": "48-833.06",
      "heading": "Penalty.",
      "text": "This subchapter may be enforced in a civil action brought by the Corporation Counsel. A manufacturer or labeler that fails to provide a report as required by this subchapter commits a civil violation for which a fine of $1,000 plus costs and attorney’s fees may be adjudged.",
      "history": "May 18, 2004, D.C. Law 15-164, § 306, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-833.06.html"
    },
    {
      "id": "section-48-833.07",
      "number": "48-833.07",
      "heading": "Rulemaking.",
      "text": "The Mayor is authorized to issue any rules necessary to implement the provisions of this subchapter.",
      "history": "May 18, 2004, D.C. Law 15-164, § 307, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-833.07.html"
    },
    {
      "id": "section-48-833.08",
      "number": "48-833.08",
      "heading": "Report.",
      "text": "The Department shall report to the committee of the Council having jurisdiction over health and human services matters on or before January 1, 2005 and on or before July 1, 2005 on the assessment of fees on manufacturers and labelers of prescription drugs.",
      "history": "May 18, 2004, D.C. Law 15-164, § 308, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-833.08.html"
    },
    {
      "id": "section-48-833.09",
      "number": "48-833.09",
      "heading": "Applicability date.",
      "text": "This subchapter shall apply as of July 1, 2004.",
      "history": "May 18, 2004, D.C. Law 15-164, § 309, 51 DCR 3688",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-833.09.html"
    },
    {
      "id": "section-48-841.01",
      "number": "48-841.01",
      "heading": "Short title.",
      "text": "This chapter may be cited as the “Off-Label Informed Consent Act of 2008”.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 201, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-841.01.html"
    },
    {
      "id": "section-48-841.02",
      "number": "48-841.02",
      "heading": "Definitions.",
      "text": "For the purposes of this chapter, the term:\n\n(1) “FDA” means the federal Food and Drug Administration.\n\n(2) “Off-label use” means the use of a prescription drug for human use to treat a condition that is not included in the labeling for that medication, as approved by the federal Food and Drug Administration.\n\n(3) “Prescriber” means a person who is licensed, registered, or otherwise authorized by the District to prescribe and administer prescription drugs for human use in the course of a professional practice.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 202, 55 DCR 1659; Mar. 25, 2009, D.C. Law 17-353, § 309(b), 56 DCR 1117",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-841.02.html"
    },
    {
      "id": "section-48-841.03",
      "number": "48-841.03",
      "heading": "Off-label use of medication.",
      "text": "Before prescribing, administering, or furnishing a prescription medication for an off-label use, a prescriber shall make every reasonable effort to:\n\n(1) Explain to the patient, in easily understood terms, that the medication is not within the uses approved for that medication by the FDA; and\n\n(2) Provide the patient with information regarding the potential risks and side effects associated with using the medication for the off-label use.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 203, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-841.03.html"
    },
    {
      "id": "section-48-841.04",
      "number": "48-841.04",
      "heading": "Penalties.",
      "text": "Failure to comply with this chapter may be used by a health-occupation board as a factor when determining licensure status for a prescriber; provided, that a prescriber shall not be subject to an adverse licensure action if the Board of Medicine determines that the prescribing, administering, or furnishing of the prescription medication for the off-label use was clearly evidence-based and the common practice within the medical community.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 204, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-841.04.html"
    },
    {
      "id": "section-48-842.01",
      "number": "48-842.01",
      "heading": "Short title.",
      "text": "This chapter may be cited as the “Medication Advisory Committee Receiving Gifts or Remuneration Prohibition Act of 2008”.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 301, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-842.01.html"
    },
    {
      "id": "section-48-842.02",
      "number": "48-842.02",
      "heading": "Definitions.",
      "text": "For the purposes of this chapter, the term:\n\n(1) “Medication advisory committee” means any committee or panel that is responsible for making recommendations or decisions regarding a formulary to be used by a health program administered by the government of the District of Columbia.\n\n(2) “Pharmaceutical company” means any entity that is engaged in, either directly or indirectly, the production, preparation, propagation, compounding, manufacturing, conversion or processing of a drug or biological product, including any person acting as its agent or representative.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 302, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-842.02.html"
    },
    {
      "id": "section-48-842.03",
      "number": "48-842.03",
      "heading": "Prohibition on gifts and remuneration.",
      "text": "(a) A pharmaceutical company shall not offer a gift or remuneration of any kind to a member of a medication advisory committee.\n\n(b) A member of a medication advisory committee shall not accept a gift or remuneration of any kind from a pharmaceutical company.\n\n(c) Nothing in this section shall prohibit the offering or acceptance of medication samples to members of a medication advisory committee who are licensed physicians engaged in the practice of medicine.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 303, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-842.03.html"
    },
    {
      "id": "section-48-842.04",
      "number": "48-842.04",
      "heading": "Penalties.",
      "text": "A violation of this chapter shall be punishable by a fine of $1,000 per violation.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 304, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-842.04.html"
    },
    {
      "id": "section-48-843.01",
      "number": "48-843.01",
      "heading": "Short title.",
      "text": "This chapter may be cited as the “Pharmaceutical Education Program Establishment Act of 2008”.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 401, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-843.01.html"
    },
    {
      "id": "section-48-843.02",
      "number": "48-843.02",
      "heading": "Definitions.",
      "text": "For the purposes of this chapter, the term “pharmaceutical product” shall have the same meaning as provided in § 3-1201.02(10A)(B)(iii).",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 402, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-843.02.html"
    },
    {
      "id": "section-48-843.03",
      "number": "48-843.03",
      "heading": "Establishment of the Pharmaceutical Education Program.",
      "text": "(a) There is established an evidence-based Pharmaceutical Education Program (“Program”) within the Department of Health. The Program shall:\n\n(1) Educate prescribers who participate in the District of Columbia Medicaid program, and other publicly funded, contracted, or subsidized health-care programs, on the therapeutic and cost-effective utilization of pharmaceutical products;\n\n(2) Inform prescribers about pharmaceutical product marketing practices that are intended to circumvent competition from generic, other therapeutically-equivalent alternatives, or other evidence-based treatment options; and\n\n(3) Utilize, or incorporate into the Program, other independent educational resources or models proven effective in promoting high-quality, evidenced-based, cost-effective information regarding the effectiveness and safety of pharmaceutical products.\n\n(b) The Program shall be made available to prescribers who do not participate in the District of Columbia Medicaid program or other publicly funded, contracted, or subsidized health-care programs on a subscription basis.\n\n(c) If approved by the Board of Medicine, the PE program may be used to satisfy continuing education requirements for the practice of medicine.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 403, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-843.03.html"
    },
    {
      "id": "section-48-843.04",
      "number": "48-843.04",
      "heading": "Applicability.",
      "text": "This chapter shall apply upon inclusion of its fiscal effect in an approved budget and financial plan.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 404, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-843.04.html"
    },
    {
      "id": "section-48-844.01",
      "number": "48-844.01",
      "heading": "Short title.",
      "text": "This chapter may be cited as the “SafeRX Evaluation Act of 2008”.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 501, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-844.01.html"
    },
    {
      "id": "section-48-844.02",
      "number": "48-844.02",
      "heading": "Definitions.",
      "text": "For the purposes of this chapter, the term:\n\n(1) “Pharmaceutical product” shall have the same meaning as provided in § 3-1201.02(10A)(B)(iii).\n\n(2) “Practice of pharmaceutical detailing” shall have the same meaning as provided in § 3-1201.02(10A) [§ 3-1201.02(10A)(A)].",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 502, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-844.02.html"
    },
    {
      "id": "section-48-844.03",
      "number": "48-844.03",
      "heading": "Evaluation.",
      "text": "(a) Within 60 days of September 30, 2010, the Department of Health shall submit to the Council a comprehensive evaluation on the effectiveness of the SafeRx Amendment Act of 2008, effective March 26, 2008 (D.C. Law 17-131), which shall include:\n\n(1) The number of individuals licensed to engage in the practice of pharmaceutical detailing since March 26, 2008;\n\n(2) The number of applicants for licensure to engage in the practice of pharmaceutical detailing not approved by the Board of Pharmacy;\n\n(3) The number of applicants for licensure to engage in the practice of pharmaceutical detailing for whom the educational requirements were waived;\n\n(4) An assessment of the appropriateness and efficacy of the continuing education requirements established pursuant to D.C. Law 17-131;\n\n(5) The number of individuals identified as engaging in the practice of pharmaceutical detailing without a license;\n\n(6) The amount of fines levied against persons charged with engaging in the practice of pharmaceutical detailing without a license;\n\n(7) The total amount and origin of revenue deposited into the Board of Pharmacy Fund;\n\n(8) The total amount of funds deposited into the Board of Pharmacy Fund that were used for the administration of the duties of the Board of Pharmacy;\n\n(9) The number and types of penalties levied for failure to comply with the requirements of off-label use of medication as set forth in § 48-841.03;\n\n(10) The number and amount of fines levied for violations as a result of pharmaceutical companies offering gifts or remuneration in violation of § 48-842.03;\n\n(11) The number of persons who participated in the Pharmaceutical Education Program established by § 48-843.03;\n\n(12) An assessment of the quality and effectiveness of the Pharmaceutical Education Program based on an assessment of data gathered from those who participated in the program. The data may be gathered by surveying those who participated in the program, using an evaluative instrument developed for that purpose;\n\n(13) An assessment of the extent to which regulation of the practice of pharmaceutical detailing has improved the practice of selling, providing information about, or promoting a pharmaceutical product.\n\n(b) The evaluation may be used to determine if D.C. Law 17-131 should be repealed or amended.",
      "history": "Mar. 26, 2008, D.C. Law 17-131, § 503, 55 DCR 1659",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-844.03.html"
    },
    {
      "id": "section-48-851.01",
      "number": "48-851.01",
      "heading": "Definitions.",
      "text": "For the purposes of this chapter, the term:\n\n(1) “Health care facility” means a hospital, assisted living facility, nursing home, or institutional pharmacy.\n\n(2) “Institutional pharmacy” means that physical portion of a health care facility where drugs, devices, and other materials used in the diagnosis or treatment of injury, illness, and disease are dispensed, compounded, or distributed and pharmaceutical care is provided.\n\n(3) “Pharmaceutical product” means a drug or biologic for human use regulated by the federal Food and Drug Administration.\n\n(4) “Retail pharmacy” means a pharmacy that provides services to the public on an outpatient basis.",
      "history": "Mar. 5, 2010, D.C. Law 18-112, § 2, 56 DCR 9378",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-851.01.html"
    },
    {
      "id": "section-48-851.02",
      "number": "48-851.02",
      "heading": "Safe disposal of unused pharmaceuticals.",
      "text": "(1) The Board of Pharmacy shall design a public education campaign to educate individuals on:\n\n(A) The importance of promptly disposing of unused pharmaceuticals to avoid accidental overdoses, medication errors, and household drug theft;\n\n(B) How disposing of pharmaceuticals by flushing them into the public sewer system or throwing them in the trash can be harmful to the environment and can contaminate the drinking water supply; and\n\n(C) How to dispose of unused pharmaceuticals in a safe and environmentally sound manner.\n\n(2) Each retail pharmacy licensed in the District of Columbia shall implement the public education campaign as required by the Board of Pharmacy.\n\n(1) By July 1, 2010, the Board of Pharmacy shall make recommendations to the Mayor regarding the establishment of a program to enable consumers to dispose of unused pharmaceuticals, including controlled substances, in a safe and environmentally sound manner.\n\n(2) In developing recommendations, the Board of Pharmacy shall give consideration to a mail-in program that:\n\n(A) Utilizes prepaid mailing envelopes that allow an individual to mail unused pharmaceuticals to a single collection location approved for all pharmaceuticals including controlled substances;\n\n(B) Distributes the prepaid mailing envelopes to the public at various locations, including to all retail pharmacies;\n\n(C) Provides for the collected pharmaceuticals to be disposed of in a manner that is:\n\n(i) Safe;\n\n(ii) Secure;\n\n(iii) Environmentally sound; and\n\n(iv) In compliance with District and federal environmental requirements; and\n\n(D) Randomly assesses the toxicity of pharmaceuticals received; provided, that the assessment results do not identify the:\n\n(i) Patient;\n\n(ii) Person who mailed the material;\n\n(iii) Prescriber; or\n\n(iv) Pharmacy.",
      "history": "Mar. 5, 2010, D.C. Law 18-112, § 3, 56 DCR 9378",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-851.02.html"
    },
    {
      "id": "section-48-851.03",
      "number": "48-851.03",
      "heading": "Disposal of pharmaceuticals by health care facilities.",
      "text": "(a) Effective January 1, 2011, it shall be unlawful for a health care facility to dispose of any pharmaceutical product, used or unused, by flushing the product down a drain or by any other method that utilizes the public sewer system, except as authorized by the Mayor through rulemaking.\n\n(b) A health care facility that is determined to have disposed of a pharmaceutical product in a manner prohibited by this chapter or by rules issued pursuant to this chapter shall be subject to a civil fine of up to $1,000 per occurrence and required to submit to the Board of Pharmacy a mitigation plan designed to prevent further occurrences.",
      "history": "Mar. 5, 2010, D.C. Law 18-112, § 4, 56 DCR 9378",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-851.03.html"
    },
    {
      "id": "section-48-851.04",
      "number": "48-851.04",
      "heading": "Rules.",
      "text": "(a) The Mayor, pursuant to subchapter I of Chapter 5 of Title 2 [§ 2-501 et seq.], shall issue rules to implement the provisions of § 48-851.03. The rules shall specify safe, secure, and environmentally sound methods for health care facilities to dispose of used and unused pharmaceuticals.\n\n(b) The Mayor, pursuant to subchapter I of Chapter 5 of Title 2 [§ 2-501 et seq.], may issue rules to implement the provisions of § 48-851.02.",
      "history": "Mar. 5, 2010, D.C. Law 18-112, § 5, 56 DCR 9378",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-851.04.html"
    },
    {
      "id": "section-48-852.01",
      "number": "48-852.01",
      "heading": "Definitions.",
      "text": "Repealed.",
      "history": "",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-852.01.html"
    },
    {
      "id": "section-48-852.02",
      "number": "48-852.02",
      "heading": "Safe disposal of controlled substances.",
      "text": "Repealed.",
      "history": "",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-852.02.html"
    },
    {
      "id": "section-48-852.03",
      "number": "48-852.03",
      "heading": "Collection by law enforcement.",
      "text": "Repealed.",
      "history": "",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-852.03.html"
    },
    {
      "id": "section-48-852.04",
      "number": "48-852.04",
      "heading": "Registrants authorized to collect; authorized collection activities.",
      "text": "Repealed.",
      "history": "",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-852.04.html"
    },
    {
      "id": "section-48-852.05",
      "number": "48-852.05",
      "heading": "Collection receptacles.",
      "text": "Repealed.",
      "history": "",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-852.05.html"
    },
    {
      "id": "section-48-852.06",
      "number": "48-852.06",
      "heading": "Collection receptacles at long-term care facilities.",
      "text": "Repealed.",
      "history": "",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-852.06.html"
    },
    {
      "id": "section-48-852.07",
      "number": "48-852.07",
      "heading": "Applicability.",
      "text": "Repealed.",
      "history": "",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-852.07.html"
    },
    {
      "id": "section-48-853.01",
      "number": "48-853.01",
      "heading": "Definitions.",
      "text": "For the purposes of this chapter, the term:\n\n(1) “Administer” shall have the same meaning as provided in § 48-901.02(1).\n\n(2) “Controlled substance” shall have the same meaning as provided in § 48-901.02(4).\n\n(3) “Controlled Substances Act” means Unit A of Chapter 9 of this title [§ 48-901.01 et seq.].\n\n(4) “Covered substance” means all controlled substances included in the schedules set forth in §§ 48-902.06, 48-902.08, 48-902.10, and 48-902.12, in schedules II through V of section 202(c) of Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, approved October 27, 1970 (84 Stat. 1247; 21 U.S.C. § 812), and any other drug, as specified by rulemaking, that is required to be reported to the Prescription Drug Monitoring Program pursuant to this chapter.\n\n(5) “Department” means the Department of Health.\n\n(6) “Director” means the Director of the Department of Health.\n\n(7) “Dispense” shall have the same meaning as provided in § 48-901.02(7).\n\n(8) “Dispenser” means a practitioner who dispenses a covered substance to the ultimate user, or his or her agent, but shall not include:\n\n(A) A licensed hospital or institutional facility pharmacy that distributes covered substances for the purpose of inpatient hospital care or the dispensing of prescriptions for controlled substances at the time of discharge from such a facility;\n\n(B) A practitioner or other authorized person who administers a covered substance;\n\n(C) A wholesale distributor of a covered substance; or\n\n(D) A clinical researcher providing a covered substance to research subjects as part of a research study approved by a hospital-based institutional review board or an institutional review board accredited by the association for the accreditation of human research protections programs.\n\n(9) “Drug” means:\n\n(A) Any substance recognized as a drug, medicine, or medicinal chemical in the official United States Pharmacopoeia, official National Formulary, official Homeopathic Pharmacopoeia, or official Veterinary Medicine Compendium or other official drug compendium or any supplement to any of them;\n\n(B) Any substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animal;\n\n(C) Any chemical substance, other than food, intended to affect the structure or any function of the body of man or other animal; and\n\n(D) Any substance intended for use as a component of any items specified in subparagraph (A), (B), or (C) of this paragraph, but does not include medical devices or their components, parts, or accessories.\n\n(10) “Health occupations board” means a board that, pursuant to § 3-1204.08, licenses and regulates health professionals with the authority to prescribe or dispense covered substances.\n\n(11) “Interoperability” means, with respect to a District of Columbia or state prescription drug monitoring program, the ability of that program to share electronically reported prescription information with another state, district, or territory of the United States’ prescription drug monitoring program or a third party, approved by the Director, that operates interstate prescription drug monitoring exchanges.\n\n(12) “Patient” means the person or animal who is the ultimate user of a controlled substance or other drug required to be submitted under this chapter for whom a lawful prescription is issued or for whom a controlled substance or such other drug is lawfully dispensed.\n\n(13) “Practitioner” shall have the same meaning as provided in § 48-901.02(20).\n\n(14) “Prescriber” means a practitioner or other authorized person who prescribes a controlled substance or other covered substance in the course of his or her professional practice.\n\n(15) “Prescription drug monitoring program” means a program that collects, manages, analyzes, and provides information regarding covered substances or other drugs required to be submitted under this chapter or a program established by a similar act in another state, district, or territory of the United States.\n\n(16) “Program” means the Prescription Drug Monitoring Program established by § 48-853.02.\n\n(17) “Ultimate user” shall have the same meaning as provided in § 48-901.02(23).",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 2, 61 DCR 7",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.01.html"
    },
    {
      "id": "section-48-853.02",
      "number": "48-853.02",
      "heading": "Program establishment; Director’s authority.",
      "text": "(a) There is established the Prescription Drug Monitoring Program within the Department. The Program shall:\n\n(1) Establish, maintain, and administer an electronic system to monitor the dispensing of covered substances;\n\n(2) Provide dispensers with a basic file layout to enable electronic transmission of the information required under this chapter; and\n\n(3) Establish and maintain a process for verifying the credentials of and authorizing the use of prescription information by those individuals and agencies listed in § 48-853.05(b) and (c).\n\n(b) The Director may contract with another District agency or a private vendor as may be necessary for the implementation and maintenance of the Program. Any such contractor shall be bound to comply with the provisions regarding confidentiality of data in this chapter and shall be subject to the penalties specified in this chapter.\n\n(c) The Director shall also establish a multi-discipline advisory committee, which shall function under the Department to assist in the implementation and evaluation of the Program.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 3, 61 DCR 7",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.02.html"
    },
    {
      "id": "section-48-853.03",
      "number": "48-853.03",
      "heading": "Reporting requirements; exceptions.",
      "text": "(1) Each dispenser shall submit to the Program the required reporting information for each prescription dispensed for a covered substance within 24 hours after the covered substance is dispensed, unless otherwise established by the Director through rulemaking, but this does not include merely placing the covered substance prescription into a bin for pickup by the ultimate user or his or her agent.\n\n(2) Any dispenser located outside the boundaries of the District that is licensed or registered by the District, shall submit the required reporting information to the Program for each prescription dispensed for a covered substance to an ultimate user who resides within the District within 24 hours after the date that the covered substance is dispensed, unless otherwise established by the Director through rulemaking.\n\n(b) The failure of any person subject to the reporting requirements of this chapter to report the dispensing of a covered substance, unless otherwise exempted under this chapter, or the willful failure to transmit accurate information shall constitute grounds for:\n\n(1) The revocation, suspension, or denial of a District controlled substances registration;\n\n(2) Disciplinary action by the relevant health occupations board pursuant to § 3-1205.14(c); and\n\n(3) The imposition of civil fines pursuant to § 2-1801.04.\n\n(c) Upon dispensing a covered substance, the dispenser of the covered substance shall report the following information to the Program:\n\n(1) Patient name;\n\n(2) Patient address;\n\n(3) Patient date of birth;\n\n(4) Patient gender;\n\n(5) Dispenser identification number;\n\n(6) Prescriber identification number;\n\n(7) Date prescription was issued by prescriber;\n\n(8) Date prescription was dispensed;\n\n(9) Prescription number;\n\n(10) Prescription type, whether the prescription is new or is a refill;\n\n(11) National Drug Code for the drug dispensed;\n\n(12) Quantity dispensed;\n\n(13) Number of days’ supply dispensed;\n\n(14) Number of refills ordered;\n\n(15) Source of payment for the prescription; and\n\n(16) Any other required information as specified in the regulations promulgated by the Director to implement this chapter, or as required for the Program to be eligible to receive federal funds.\n\n(d) Each dispenser shall transmit the required reporting information in accordance with the manner, format, standards, and schedules established by the Director through rulemaking.\n\n(e) The reporting requirements of this chapter shall not apply to the dispensing of covered substances when the dispensing is limited to the following:\n\n(1) Administering covered substances;\n\n(2) Dispensing covered substances within an appropriately licensed narcotic maintenance program;\n\n(3) Dispensing covered substances to inpatients in hospitals or nursing facilities licensed by the Department or facilities that are otherwise authorized by law to operate as hospitals or nursing homes in the District;\n\n(4) Dispensing covered substances to inpatients in hospices licensed by the Department; or\n\n(5) Dispensing covered substances as otherwise provided in the Department’s regulations.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 4, 61 DCR 7",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.03.html"
    },
    {
      "id": "section-48-853.03a",
      "number": "48-853.03a",
      "heading": "Registration requirement for prescribers and dispensers.",
      "text": "Repealed.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 4a",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.03a.html"
    },
    {
      "id": "section-48-853.03b",
      "number": "48-853.03b",
      "heading": "Registration requirement for practitioners and dispensers.",
      "text": "(a) Any practitioner who is licensed, registered, or otherwise permitted to prescribe, distribute, dispense, conduct research with respect to, or to administer a controlled substance or other covered substance in the course of his or her professional practice, and any dispenser who is licensed in the District of Columbia to dispense a controlled substance or other covered substance to an ultimate user, the user's agent, or owner in the case of animals, shall be registered with the Program.\n\n(b) Beginning 90 days afterJune 24, 2020, each practitioner or dispenser who is required to be registered with the Program, pursuant to subsection (a) of this section, shall register with the Program within 90 days of obtaining a new health professional license or before renewing an existing health professional license, whichever occurs first.\n\n(c) The Health Occupations Boards shall not approve a practitioner or dispenser, who is required to be registered with the Program pursuant to subsection (a) of this section, for reinstatement, reactivation, or renewal of licensure without proof that the practitioner or dispenser has registered with the Program as required.\n\n(d) Failure to timely register with the Program shall constitute grounds for disciplinary action by the relevant health occupations board pursuant to § 3-1205.14(c), and the imposition of civil fines pursuant to § 2-1801.04.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 4b",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.03b.html"
    },
    {
      "id": "section-48-853.03c",
      "number": "48-853.03c",
      "heading": "Database Query requirement for prescribers and dispensers.",
      "text": "(1) Except as provided in subsection (c) of this section, a prescriber who is licensed, registered, or otherwise permitted to prescribe a controlled substance or other covered substance in the course of his or her professional practice in the District of Columbia, or the prescriber's authorized delegee, shall query the District of Columbia prescription drug monitoring database before initiating a new course of treatment or therapy for a patient in the District of Columbia that includes prescribing an opioid or benzodiazepine for more than 7 consecutive days, and every 90 days thereafter while the course of treatment or therapy continues.\n\n(2) Nothing in this subsection shall prohibit a prescriber from making additional periodic queries of the prescription drug monitoring program database as may be required by routine prescribing practices.\n\n(1) Except as provided in subsection (c) of this section, a dispenser who is licensed, registered, or otherwise permitted to dispense a controlled substance or other covered substance in the course of his or her professional practice in the District of Columbia, or the dispenser's authorized delegee, shall query the District of Columbia prescription drug monitoring database before dispensing an opioid or benzodiazepine for a course of treatment that is anticipated to last for more than 7 consecutive days, and before dispensing a refill for an opioid or benzodiazepine more than 90 days after the initial fill or previous refill date.\n\n(2) Nothing in this section shall prohibit a dispenser from making additional periodic queries of the prescription drug monitoring program database as may be required by routine prescribing practices.\n\n(c) A prescriber or dispenser shall not be required to meet the provisions of subsection (a) or (b) of this section if the:\n\n(1) Controlled substance or other covered substance is prescribed or otherwise provided to a patient currently receiving hospice or palliative care;\n\n(2) Controlled substance or other covered substance is prescribed or otherwise provided to a patient during an inpatient hospital admission or at discharge;\n\n(3) Controlled substance or other covered substance is prescribed or otherwise provided to a patient in a nursing home or residential care facility that uses a sole source pharmacy;\n\n(4) Prescription drug monitoring program database is not operational or available due to a temporary technological or electrical failure or natural disaster; or\n\n(5) Prescriber or dispenser is unable to access the prescription drug monitoring program database due to an emergency or a disaster and documents the circumstances in the patient's medical record.\n\n(d) Failure to comply with the provisions of this section shall constitute grounds for disciplinary action by the relevant health occupations board pursuant to § 3-1205.14(c) and the imposition of civil fines pursuant to § 2-1801.04.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 4c",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.03c.html"
    },
    {
      "id": "section-48-853.04",
      "number": "48-853.04",
      "heading": "Authority to access database.",
      "text": "(a) A prescriber or dispenser authorized to access the information in the possession of the Program pursuant to this chapter may delegate, pursuant to regulations promulgated by the Director to implement the provisions of this section, such authority to up to 2 health care professionals who are:\n\n(1) Licensed, registered, or certified by a health occupations board; and\n\n(2) Employed at the same facility and under the direct supervision of the prescriber or dispenser.\n\n(b) No prescriber or dispenser shall provide false or misleading information to the Department with the intent to obtain unauthorized access to, or alter the information in the possession of the Program.\n\n(c) A violation of subsection (b) of this section shall constitute grounds for:\n\n(1) The revocation, suspension, or denial of a District controlled substances registration;\n\n(2) Disciplinary action by the relevant health occupations board pursuant to § 3-1205.14(c); and\n\n(3) The imposition of civil fines pursuant to § 2-1801.04.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 5, 61 DCR 7",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.04.html"
    },
    {
      "id": "section-48-853.05",
      "number": "48-853.05",
      "heading": "Confidentiality of data; disclosure of information; discretionary authority of the Director.",
      "text": "(a) All data, records, and reports relating to the prescribing and dispensing of covered substances to patients and any abstracts from such data, records, and reports that are in the possession of the Program pursuant to this chapter and any materials relating to the operation or safety of the Program shall be confidential and shall be exempt from disclosure based on requests made pursuant to subchapter II of Chapter 5 of Title 2 [§ 2-531 et seq.]. Information obtained pursuant to the Program may only be disclosed as provided in this chapter.\n\n(b) Upon receiving a request for information in accordance with the Department’s regulations and in compliance with applicable District and federal laws and regulations, the Director shall disclose information relevant to:\n\n(1) A specific investigation of a specific patient or of a specific dispenser or prescriber to an agent designated by the Chief of the Metropolitan Police Department to conduct drug diversion investigations;\n\n(2) An investigation or inspection of or allegation of misconduct by a specific person licensed, certified, or registered by or an applicant for licensure, certification, or registration by a health occupations board or the Department;\n\n(3) A disciplinary proceeding before a health occupations board or in any subsequent hearing, trial, or appeal of an action or board order to designated employees of the Department;\n\n(4) The proceedings of any grand jury or additional grand jury that has been properly impaneled in accordance with § 11-1916; and\n\n(5) A specific investigation of a specific patient or of a specific dispenser or prescriber to an agent of a federal law-enforcement agency with authority to conduct drug diversion investigations.\n\n(1) In accordance with the Department’s regulations and applicable federal law and regulations, the Director may, at the Director’s discretion, disclose:\n\n(A) Information in the possession of the Program concerning a patient who is over the age of 18 years to that patient, or to the parent or legal guardian of a child aged 18 years or under, unless otherwise prohibited by District or federal law;\n\n(B) Information on a specific patient to a prescriber for the purpose of establishing the treatment history of the specific patient when the patient is either under care and treatment by the prescriber or the prescriber is initiating treatment of the patient;\n\n(C) Information on a specific patient to a dispenser for the purpose of establishing a prescription history to assist the dispenser in determining the validity of a prescription when the patient is seeking a covered substance from the dispenser or the facility in which the dispenser practices;\n\n(D) Information relevant to an investigation or regulatory proceeding of a specific dispenser or prescriber to other regulatory authorities concerned with granting, limiting, or denying licenses, certificates, or registrations to practice a health profession when the regulatory authority licenses the dispenser or prescriber, or the dispenser or prescriber is seeking licensure by a regulatory authority;\n\n(E) Information relevant to an investigation relating to a specific dispenser or prescriber who is a participating provider in the District Medicaid program, DC Health Care Alliance, or any other public health care program; information relating to an investigation relating to a specific patient who is currently eligible for and receiving, or who has been eligible for and has received medical assistance services; information relevant to the Medicaid Fraud Control Unit of the Office of the Inspector General, or to designated employees of the Department of Health Care Finance, as appropriate;\n\n(F) Information relevant to the determination of the cause of death of a specific patient to the designated employees of the Office of the Chief Medical Examiner;\n\n(G) Information for the purpose of bona fide research or education to qualified personnel; provided, that:\n\n(i) Data elements that would reasonably identify a specific patient, prescriber, or dispenser shall be deleted or redacted from the information before disclosure; and\n\n(ii) Release of the information shall only be made pursuant to a written agreement between qualified personnel and the Director to ensure compliance with this chapter;\n\n(H) Aggregate and summary data that has been processed to remove information that could be used to reasonably identify a specific patient, prescriber, or dispenser to a person for statistical, research, educational, or grant application purposes; and\n\n(I) Information for the purpose of public health surveillance to employees of the Department's Center for Policy, Planning, and Evaluation; provided, that:\n\n(i) Data elements that would identify a specific patient, prescriber, or dispenser shall be deleted or redacted from the information before disclosure; and\n\n(ii) Release of the information shall only be made pursuant to a written agreement between the employees of the Center for Policy, Planning, and Evaluation and the Director to ensure compliance with this chapter.\n\n(2) For the purposes of a disclosure under paragraph (1)(B) or (C) of this subsection:\n\n(A) The request shall be made and the information shall be provided in the manner specified by the Director through rulemaking; and\n\n(B) Notice shall be given to patients that the information described in paragraph (1)(B) or (C) of this subsection, as applicable, may be requested by a prescriber or dispenser participating with the Program.\n\n(3) For a disclosure made under paragraph (1)(G) or (H) of this subsection, the Director may establish and collect fees to recover the operational costs associated with the disclosure, including the costs associated with reaching a data sharing agreement, monitoring user compliance with the data sharing agreement, and searching, aggregating, anonymizing, sampling, and cleaning the data.\n\n(4) All fees collected pursuant to paragraph (3) of this subsection shall be deposited as nonlapsing funds in the Health Occupations Regulation Fund established by § 7-733.\n\n(d) Confidential information that has been received, maintained, or developed by a health occupations board or disclosed by the health occupations board pursuant to this chapter shall not be available for discovery or court subpoena or introduced into evidence in any medical malpractice suit or other action for damages arising out of the provision of or failure to provide services; provided, that this section shall not be construed to inhibit any investigation or prosecution conducted pursuant to this chapter.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 6, 61 DCR 7",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.05.html"
    },
    {
      "id": "section-48-853.06",
      "number": "48-853.06",
      "heading": "Interoperability; information exchange with other prescription drug monitoring programs.",
      "text": "(a) The Director may enter into written agreements with other prescription drug monitoring programs, or a third party, approved by the Director, that operates an interstate prescription drug monitoring exchange, for the purpose of interoperability and the mutual exchange of information among prescription drug monitoring programs, and describing the terms and conditions for the sharing of prescription information under this section.\n\n(b) The Director may provide prescription monitoring information pursuant to such agreements, which shall only use the information for the purposes allowed by this chapter.\n\n(c) The Director may request and receive prescription drug monitoring information from other states’ prescription drug monitoring programs and may use the information under the provisions of this chapter.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 7, 61 DCR 7",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.06.html"
    },
    {
      "id": "section-48-853.07",
      "number": "48-853.07",
      "heading": "Criteria for indicators of misuse; Director’s authority to disclose information; intervention.",
      "text": "(a) The Director may establish through rulemaking:\n\n(1) Criteria for indicators of misuse or abuse of covered substances;\n\n(2) A method for analysis of data collected by the Program using the criteria for indicators of misuse or abuse of covered substances;\n\n(3) Criteria for indications of a possible violation of law or a possible breach of professional standards by a prescriber or dispenser; and\n\n(4) A method for analysis of data collected by the Program using the criteria for indications of a possible violation of law or a possible breach of professional standards by a prescriber or dispenser.\n\n(1) Upon the development of the criteria and data analysis, the Program may review prescription monitoring program data for indications of:\n\n(A) Possible misuse or abuse of a covered prescription drug; and\n\n(B) A possible violation of law or possible breach of professional standards by a prescriber or a dispenser.\n\n(2) If the Program's review of prescription monitoring data indicates a possible violation of paragraph (1) of this subsection, the Director may, in addition to any discretionary disclosure of information pursuant to this chapter:\n\n(A) Report the possible misuse or abuse by a patient to the specific prescriber or dispenser of the covered prescription drug for the purpose of intervention to prevent such misuse or abuse;\n\n(B) Notify the prescriber or dispenser of the possible violation of law or possible breach of professional standards; and\n\n(C) Provide education to the prescriber or dispenser.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 8, 61 DCR 7",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.07.html"
    },
    {
      "id": "section-48-853.08",
      "number": "48-853.08",
      "heading": "Immunity from liability.",
      "text": "(a) The Director and the employees of the Department shall not be liable for any civil damages resulting from the accuracy or inaccuracy of any information reported, compiled, or maintained by the Program pursuant to this chapter.\n\n(b) The Director and the employees of the Department shall not be liable for any civil damages resulting from the disclosure of or failure to disclose any information in compliance with this chapter and the Department’s regulations.\n\n(c) In the absence of gross negligence or willful misconduct, prescribers or dispensers complying in good faith with the reporting requirements of this chapter shall not be liable for any civil damages for any act or omission resulting from the submission of such required reports.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 9, 61 DCR 7",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.08.html"
    },
    {
      "id": "section-48-853.09",
      "number": "48-853.09",
      "heading": "Unlawful disclosure of information and acts; disciplinary action authorized; penalties.",
      "text": "(a) It shall be unlawful for any person having access to the confidential information in possession of the Program or any data or reports produced by the Program to disclose the confidential information except as provided in this chapter. Any person who discloses this confidential information in violation of the provisions of this chapter shall be guilty of a misdemeanor upon conviction.\n\n(b) It shall be unlawful for any person who lawfully receives confidential information from the Program to redisclose or use the confidential information in any way other than the authorized purpose for which the request was made. Any person who discloses confidential information in violation of this chapter shall be guilty of a misdemeanor upon conviction.\n\n(c) Nothing in this section shall prohibit a person who prescribes or dispenses a covered substance required to be reported to the program from redisclosing information obtained from the Program to another prescriber or dispenser who has prescribed or dispensed a covered substance to the same patient.\n\n(d) Unauthorized use or disclosure of confidential information received from the Program shall also be grounds for disciplinary action by the relevant health occupations board.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 10, 61 DCR 7",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.09.html"
    },
    {
      "id": "section-48-853.10",
      "number": "48-853.10",
      "heading": "Rules.",
      "text": "The Director, pursuant subchapter I of Chapter 5 of Title 2 [§ 2-501 et seq.], shall issue rules to implement the provisions of this chapter, including the establishment of criteria for granting waivers to the reporting requirements set forth in this chapter.",
      "history": "Feb. 22, 2014, D.C. Law 20-66, § 11, 61 DCR 7",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-853.10.html"
    },
    {
      "id": "section-48-855.01",
      "number": "48-855.01",
      "heading": "Definitions.",
      "text": "For the purposes of this chapter, the term:\n\n(1) \"Class of drugs\" means a group of medications having similar actions designed to treat a particular disease process.\n\n(2) \"Coinsurance\" means a cost-sharing amount set as a percentage of the total cost of a drug.\n\n(3) \"Copayment\" means a cost-sharing amount set as a dollar value.\n\n(3A) \"Diabetes device\" means a legend device or non-legend device used to cure, diagnose, mitigate, prevent or treat diabetes or low blood sugar. The term includes a blood glucose test strip, glucometer, continuous glucometer, lancet, lancing device, or insulin syringe.\n\n(3B) \"Diabetic ketoacidosis device\" means a device that is a legend or non-legend device and used to screen for or prevent diabetic ketoacidosis. The term includes diabetic ketoacidosis devices prescribed and dispensed once during a policy year.\n\n(3C) \"Generic drug\" means a chemically equivalent copy of a brand-name drug with an expired patent.\n\n(A) \"Health benefit plan\" means a policy, contract, certificate, or agreement offered or issued by a health carrier to provide, deliver, arrange for, pay for, or reimburse any of the costs of health care services.\n\n(B) The term \"health benefit plan\" does not include:\n\n(i) Coverage only for accident or disability income insurance, or any combination thereof;\n\n(ii) Liability insurance, including general liability insurance and automobile liability insurance;\n\n(iii) Coverage issued as a supplement to liability insurance;\n\n(iv) Workers' compensation or similar insurance;\n\n(v) Automobile medical payment insurance;\n\n(vi) Credit-only insurance;\n\n(vii) Coverage for on-site medical clinics; or\n\n(viii) Other similar insurance coverage specified in federal regulations issued pursuant to the Health Insurance Portability and Accountability Act of 1996, approved August 21, 1996 (110 Stat. 1936; scattered sections of the United States Code) (\"HIPAA\"), under which benefits for health care services are secondary or incidental to other insurance benefits.\n\n(C) The term \"health benefit plan\" does not include the following benefits if they are provided under a separate policy, certificate of insurance, or contract of insurance, or are otherwise not an integral part of the plan:\n\n(i) Limited scope dental or vision benefits;\n\n(ii) Benefits for long-term care, nursing-home care, home-health care, community-based care, or any combination thereof; or\n\n(iii) Other similar, limited benefits specified in federal regulations issued pursuant to HIPAA.\n\n(D) The term \"health benefit plan\" does not include the following benefits if the benefits are provided under a separate policy, certificate of insurance, or contract of insurance, and there is no coordination between the provision of the benefits and any exclusion of benefits under any group health plan maintained by the same health insurer, and the benefits are paid with respect to an event without regard to whether benefits are provided with respect to such an event under any group health plan maintained by the same health insurer:\n\n(i) Coverage only for a specified disease or illness; or\n\n(ii) Hospital indemnity or other fixed indemnity insurance.\n\n(E) The term \"health benefit plan\" does not include the following if offered as a separate policy, certificate of insurance, or contract of insurance:\n\n(i) A Medicare supplemental policy as defined in section 1882(g)(1) of the Social Security Act, approved June 9, 1980 (94 Stat. 476; 42 U.S.C. § 1395ss(g)(1));\n\n(ii) Coverage supplemental to the coverage provided under An Act To amend titles 10, 14, and 32, United States Code, to codify recent military law, and to improve the Code, approved September 2, 1958 (72 Stat. 1437; 10 U.S.C. § 1071 et seq.); or\n\n(iii) Similar supplemental coverage provided under a group health plan.\n\n(5) \"Health insurer\" means any person that provides one or more health benefit plans or insurance in the District of Columbia, including an insurer, a hospital and medical services corporation, a fraternal benefit society, a health maintenance organization, a multiple employer welfare arrangement, or any other person providing a plan of health insurance subject to the authority of the Commissioner of the Department of Insurance, Securities and Banking.\n\n(5A) \"Interchangeable biological product\" means a biological product that is licensed and determined by the Food and Drug Administration to meet the standards for interchangeability under 42 U.S.C. § 262(k)(4) or determined to be biosimilar to and interchangeable with a reference biological product as stated in the Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations, also known as the Purple Books.\n\n(6) \"Member\" means an individual who is enrolled in a health benefit plan.\n\n(7) \"Member representative\" means a:\n\n(A) Person acting on behalf of a member with the member's consent;\n\n(B) Person authorized by law to provide substituted consent for a member;\n\n(C) Family member of the member;\n\n(D) Member's treating health care professional when the member is unable to provide consent; or\n\n(E) In the case of a request regarding an emergency or urgent medical condition, a health-care professional with knowledge of the member's medical condition.\n\n(8) \"Non-preferred drug\" means a specialty drug formulary classification for certain specialty drugs that are subject to limits on eligibility for coverage or to higher cost-sharing amounts than preferred specialty drugs.\n\n(9) \"Preferred drug\" means a specialty drug formulary classification for certain specialty drugs that are not subject to limits on eligibility for coverage or to higher cost-sharing amounts than a non-preferred drug.\n\n(9A) \"Prescription insulin drug\" means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.\n\n(10) \"Specialty drug\" means a prescription drug that:\n\n(A) Is prescribed for a person with:\n\n(i) A physical, behavioral, or developmental condition that may have no known cure, is progressive, or can be debilitating or fatal if left untreated or undertreated, such as multiple sclerosis, hepatitis C, or rheumatoid arthritis; or\n\n(ii) A disease or condition that affects fewer than 200,000 persons in the United States or approximately one in 1,500 persons worldwide, such as cystic fibrosis, hemophilia, or multiple myeloma;\n\n(B) Has a total monthly prescription cost of $600 or more; and\n\n(C) Has one or more of the following characteristics:\n\n(i) Is an oral, injectable, or infusible drug product or a drug product that is delivered topically, through inhalation, implantation, or transmucosally;\n\n(ii) Requires unique storage or shipment, such as refrigeration; or\n\n(iii) Requires patient education and support beyond traditional dispensing activities.\n\n(11) \"Specialty tier\" means a tier of cost sharing designed for select specialty drugs that imposes a cost-sharing obligation that is based on a coinsurance or copayment and exceeds that amount for non-specialty drugs.\n\n(12) \"Step therapy\" means a protocol established by a health insurer that requires a prescription drug or sequence of prescription drugs to be used by an insured or an enrollee before a prescription drug ordered by a prescriber for the insured or the enrollee is covered.\n\n(13) \"Tiered formulary\" means a formulary that provides coverage for prescription drugs as part of a health benefit plan for which cost-sharing, deductibles, or coinsurance is determined by category or tier of prescription drugs, and that includes at least 2 different tiers.",
      "history": "",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-855.01.html"
    },
    {
      "id": "section-48-855.02",
      "number": "48-855.02",
      "heading": "Specialty drug copayment or coinsurance limitation.",
      "text": "(1) A health benefit plan that provides coverage for prescription drugs shall ensure that a required copayment or coinsurance applicable to a drug on a specialty tier does not exceed $150 per month for up to a 30-day supply of the specialty drug or $300 for a 90-day supply.\n\n(2) On July 1 of each year, the limit on a required copayment or coinsurance applicable to a drug on a specialty tier provided in paragraph (1) of this subsection shall increase by a percentage equal to the percentage change from the preceding year in the medical care component of the March Consumer Price Index for All Urban Consumers, Washington-Arlington-Alexandria, DC-VA-MD-WV metropolitan area, as published by the Bureau of Labor Statistics of the United States Department of Labor.\n\n(1) For a health benefit plan that provides coverage for prescription drugs and utilizes a tiered formulary, a member or member representative shall have the right to request that a non-preferred drug be covered under the cost sharing applicable for preferred drugs if the prescribing physician determines that the preferred drug for treatment of the same condition either would not be as effective for the individual or would have adverse effects for the individual, or both.\n\n(2) The denial of a request made pursuant to paragraph (1) of this subsection shall be considered an adverse event and shall be subject to the health benefit plan's internal review process.\n\n(c) A health benefit plan that provides coverage for prescription drugs shall not place all drugs in a given class of drugs on a specialty tier.\n\n(d) Nothing in this section shall be construed to require a health benefit plan to:\n\n(1) Provide coverage for any additional drugs not otherwise required by law;\n\n(2) Implement specific utilization management techniques, such as prior authorization or step therapy; or\n\n(3) Cease the use of tiered cost-sharing structures, including strategies used to incentivize use of preventive services, disease management, and low-cost treatment options.\n\n(e) Nothing in this section shall be construed to require a pharmacist to substitute a drug without the consent of the prescribing physician.\n\n(f) A health insurer shall not be precluded from requiring specialty drugs to be obtained through a designated pharmacy or other source of specialty drugs.",
      "history": "",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-855.02.html"
    },
    {
      "id": "section-48-855.02a",
      "number": "48-855.02a",
      "heading": "Insulin copayment or coinsurance limitation.",
      "text": "(a) A health insurer that provides coverage for prescription insulin drugs pursuant to the terms of a health benefits plan the insurer offers shall limit the total amount that an insured is required to pay for a 30-day supply of covered prescription insulin drugs at an amount not to exceed $30, regardless of the quantity or type of covered prescription insulin drug used to fill the insured's prescription.\n\n(b) A health insurer that provides coverage for diabetes devices and diabetic ketoacidosis devices pursuant to the terms of a health benefits plan offered by the insurer, shall limit the total amount that an insured is required to pay for a 30-day supply of all medically necessary covered diabetes devices and diabetic ketoacidosis devices that are in accordance with the insured's diabetes treatment plan at an amount not to exceed $100.\n\n(c) Pursuant to subsections (a) and (b) of this section, prescription insulin drugs, diabetes devices, and diabetic ketoacidosis devices shall be covered without being subject to a deductible and any cost sharing paid by an insured shall be applied toward the insured's deductible and out of pocket maximum obligations.\n\n(d) Nothing in this section prevents an insurer from reducing an insured's copayment or coinsurance by an amount greater than the amount specified in subsections (a) and (b) of this section.\n\n(e) On July 1 of each year, the limit on a required copayment or coinsurance an insured is required to pay under subsections (a) and (b) of this section shall increase by a percentage equal to the percentage change from the preceding year in the medical care component of the Consumer Price Index for All Urban Consumers, Washington-Arlington-Alexandria, DC-VA-MD-WV metropolitan area, as published by the Bureau of Labor Statistics of the United States Department of Labor.\n\n(f) This section shall apply as of January 1, 2022.",
      "history": "April 7, 2017, D.C. Law 21-248, § 3a",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-855.02a.html"
    },
    {
      "id": "section-48-855.02b",
      "number": "48-855.02b",
      "heading": "Calculation of member's contributions for a prescription drug covered under the health benefit plan.",
      "text": "(a) Except as otherwise provided in subsection (b) of this section, when calculating a member's contribution to their coinsurance, copayment, cost-sharing responsibility, deductible, or out-of-pocket maximum under the member's health benefit plan, the health insurer shall include any discount, financial assistance payment, product voucher, or any other out-of-pocket expense made by or on behalf of the member for a prescription drug covered under the member's health benefit plan that:\n\n(1) Is without a generic drug equivalent or an interchangeable biological product preferred under the health benefit plan's formulary; or\n\n(2) Has a generic equivalent drug or an interchangeable biological product preferred under the health benefit plan's formulary where the member has obtained access to the drug through prior authorization, a step therapy protocol, or the exception or appeal process of the health insurer or pharmacy benefits manager.\n\n(b) Subsection (a) of this section shall not apply to a member covered by a high deductible health plan, as that term is defined under 26 U.S.C. § 223, until the member satisfies their minimum deductible; except, that subsection (a) of this section shall apply to contribution amounts made for preventative care, as that term is defined under 26 U.S.C. § 223(c)(2)(C).\n\n(c) This section shall apply to health benefit plans entered into, amended, extended, or renewed on or after January 1, 2025.",
      "history": "Apr. 17, 2017, D.C. Law 21-248, § 3b",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-855.02b.html"
    },
    {
      "id": "section-48-855.03",
      "number": "48-855.03",
      "heading": "Applicability.",
      "text": "This chapter shall apply to a health benefit plan effective, or renewed, on or after January 1, 2018; except, that § 48-855.02a shall apply on January 1, 2022[].",
      "history": "",
      "source_url": "https://code.dccouncil.us/us/dc/council/code/sections/48-855.03.html"
    }
  ]
}